Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7907147 | 0.90 | KDM4E (0.58) | ALDH1A1KDM4ELMNAHPGDHTT | |
| SCHEMBL5737290 | 0.87 | ALDH1A1 (0.56) | ALDH1A1KDM4ELMNAHPGDHTT | |
| SCHEMBL10750177 | 0.86 | ALDH1A1 (0.59) | ALDH1A1KDM4ELMNAHPGDHTT | |
| SCHEMBL9440112 | 0.85 | KDM4E (0.58) | ALDH1A1KDM4ELMNAHPGDHTT | |
| SCHEMBL28153879 | 0.84 | ALDH1A1 (0.61) | ALDH1A1FFAR1CA1CA2FFAR4 | |
| SCHEMBL1422341 | 0.83 | KDM4E (0.56) | ALDH1A1KDM4ELMNAHPGDHTT | |
| SCHEMBL8339606 | 0.83 | ALDH1A1 (0.57) | ALDH1A1FFAR1CA1CA2FFAR4 | |
| SCHEMBL1422207 | 0.82 | ALDH1A1 (0.63) | ALDH1A1KDM4ELMNAHPGDHTT | |
| SCHEMBL3555520 | 0.81 | KDM4E (0.59) | ALDH1A1KDM4ELMNAHPGDHTT | |
| SCHEMBL6500179 | 0.81 | FABP4 (0.57) | ALDH1A1SMN1; SMN2FFAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534693-A2 | 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| WO-2004022523-A2 | 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2004-03-18 | — | — | WO | claimed |
| EP-2170334-B1 | NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION | UNIV EMORY (US) | 2021-03-17 | — | — | EP | disclosed |
| CN-104067122-B | Based on acridine and the fluorescent dye of acridine derivatives | 艾尔玛可科学（苏格兰）有限公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-104837816-A | GPR40 receptor agonist, method for preparing same, and pharmaceutical composition containing same as active ingredient | LG LIFE SCIENCES LTD | 2015-08-12 | — | — | CN | disclosed |
| US-9079852-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | LIOTTA DENNIS C (US) | 2014-01-30 | — | — | US | disclosed |
| CN-103497114-A | NMDA receptor antagonists for neuroprotection | UNIV EMORY | 2014-01-08 | — | — | CN | disclosed |
| CN-103058957-A | NMDA receptor antagonists for neuroprotection | UNIV EMORY | 2013-04-24 | — | — | CN | disclosed |
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| CN-101815518-B | NMDA receptor antagonists for neuroprotection | UNIV EMORY | 2013-01-09 | — | — | CN | disclosed |
| WO-2009137843-A2 | NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | EMORY UNIVERSITY (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
| WO-2009006437-A1 | NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION | EMORY UNIVERSITY (US) | 2009-01-08 | — | — | WO | disclosed |
| US-5155268-A | Antiarrhythmic N-aminoalkylene alkyl and aryl sulfonamides | THE UPJOHN COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| US-4855314-A | VASOCONTRICTORS, TREATMENT OF MIGRAINES, 3-(AMINO-ETHYL)-5-(PHENYL(ALKYL)-CARBONYL OR SULFONYL-AMINOALKYL SUBSTITUTED | GLAXO GROUP LIMITED (GB) | 1989-08-08 | — | — | US | disclosed |
| CN-1030409-A | Indole derivatives and preparation method thereof | GLAXO GROUP LTD (GB) | 1989-01-18 | — | — | CN | disclosed |
| EP-0164865-B1 | N-(AMINOALKYLPHENYL)SULFONAMIDES THEIR PREPARATION AND THERAPEUTIC USE | THE UPJOHN COMPANY (US) | 1988-12-21 | — | — | EP | disclosed |
| EP-0240096-A1 | Indole derivatives having a selective vasoconstrictor activity | GLAXO GROUP LIMITED (GB) | 1987-10-07 | — | — | EP | disclosed |
| EP-0164865-A1 | N-(Aminoalkylphenyl)sulfonamides their preparation and therapeutic use | THE UPJOHN COMPANY (US) | 1985-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | ALDH1A1 2664/4885KDM4E 2576/4885LMNA 4281/4885 |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | ALDH1A1 2668/4885KDM4E 2527/4885LMNA 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.